U.S. markets closed

Selecta Biosciences, Inc. (SELB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.4600+0.1000 (+2.98%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.3600
Open3.4200
Bid3.4500 x 4000
Ask3.5600 x 4000
Day's Range3.3100 - 3.5973
52 Week Range1.4700 - 5.7000
Volume981,402
Avg. Volume1,235,400
Market Cap391.651M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.7020
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • New Strong Sell Stocks for July 14th
    Zacks

    New Strong Sell Stocks for July 14th

    COHU, NTRB, HELE, CNR, and SELB have been added to the Zacks Rank #5 (Strong Sell) List on July 14, 2021

  • Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021
    GlobeNewswire

    Selecta Biosciences to Participate at the William Blair Biotech Focus Conference 2021

    WATERTOWN, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in one-on-one investor meetings and Chief Science Officer, Takashi Kei Kishimoto, Ph.D., will participate in a panel discussion at the William Blair

  • Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors
    GlobeNewswire

    Selecta Biosciences Appoints Industry Leader Nishan de Silva, M.D. to Board of Directors

    WATERTOWN, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Nishan de Silva, M.D. to its Board of Directors. Dr. de Silva will provide strategic guidance and operational insights as Selecta continues to advance its clinical pipeline. “We are thrilled to welcome Dr. de